CEVEC Announces Appointment Of Life Sciences Industry Expert Frank Ubags As Chief Executive Officer
Cologne, Germany, April 17, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC), the provider of novel human cell expression systems, today announced the appointment of Frank Ubags as Chief Executive Officer starting immediately. He replaces Wolfgang Kintzel who is moving into the investor side of the life sciences industry. He will continue to serve as an advisor to CEVEC.
Frank Ubags joined CEVEC in October 2014 as Chief Operating Officer and Managing Director. He has over 35 years of leadership experience in renowned companies. He has successfully executed major financing transactions, turn around projects, and initiated and executed major M&A transactions in both acquiring and selling companies. Frank joined the life sciences industry in 1997 as CFO of Rhein Biotech, where he led the 1999 IPO and was responsible for the transformation of Rhein Biotech into a vaccines company followed by, two years later, a trade sale to Berna Biotech. In addition, Frank's experience has included CEO, COO and CFO positions in companies such as the German Rhein Biotech operation, Kiadis Pharma and Scil Proteins. Frank holds several advisory positions in the field of protein production.
Joachim Rautter, Chairman of the CEVEC Supervisory Board, commented: "With Frank's financial, operational and strategic track record we are well positioned to execute our financing and growth strategies. On behalf of the Board, I would like to thank Wolfgang Kintzel for his excellent work as CEO and his strategic leadership during the last six years."
"Our CAP(R) Technology is by now very well positioned in the market. It has been specifically developed to enable the industrial scale production of viral vectors for the currently exponentially growing field of gene therapy. In addition, our technology also facilitates limitless access to 'difficult to produce' proteins, coagulation factors and other plasma derived substances, allowing for broader, safer and less cost-intensive applications," explained Frank Ubags, the newly appointed Chief Executive Officer of CEVEC. "Together with the whole CEVEC team, I am looking forward to fully exploit the enormous potential of our unique assets."
About CEVEC:
CEVEC Pharmaceuticals GmbH (www.cevec.com) offers an innovative human cell expression system - CAP(R) Technology. The patented human cell lines are used for the production of gene therapy vectors, therapeutic proteins and novel innovative vaccines. A number of licensing transactions, both for R&D and clinical purposes, have already been concluded. CEVEC has recently formed a CMO joint venture partnership with GenIBet, Portugal for cGMP production services based on CAP(R) Technology.
Contact:
CEVEC Pharmaceuticals GmbH
Frank Ubags
Chief Executive Officer
T.:+49 221 46020800
E.: ubags@cevec.com
MC Services AG
Anne Hennecke
Public Relations
T.: +49 211 52925222
E.: anne.hennecke@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
Frank Ubags joined CEVEC in October 2014 as Chief Operating Officer and Managing Director. He has over 35 years of leadership experience in renowned companies. He has successfully executed major financing transactions, turn around projects, and initiated and executed major M&A transactions in both acquiring and selling companies. Frank joined the life sciences industry in 1997 as CFO of Rhein Biotech, where he led the 1999 IPO and was responsible for the transformation of Rhein Biotech into a vaccines company followed by, two years later, a trade sale to Berna Biotech. In addition, Frank's experience has included CEO, COO and CFO positions in companies such as the German Rhein Biotech operation, Kiadis Pharma and Scil Proteins. Frank holds several advisory positions in the field of protein production.
Joachim Rautter, Chairman of the CEVEC Supervisory Board, commented: "With Frank's financial, operational and strategic track record we are well positioned to execute our financing and growth strategies. On behalf of the Board, I would like to thank Wolfgang Kintzel for his excellent work as CEO and his strategic leadership during the last six years."
"Our CAP(R) Technology is by now very well positioned in the market. It has been specifically developed to enable the industrial scale production of viral vectors for the currently exponentially growing field of gene therapy. In addition, our technology also facilitates limitless access to 'difficult to produce' proteins, coagulation factors and other plasma derived substances, allowing for broader, safer and less cost-intensive applications," explained Frank Ubags, the newly appointed Chief Executive Officer of CEVEC. "Together with the whole CEVEC team, I am looking forward to fully exploit the enormous potential of our unique assets."
About CEVEC:
CEVEC Pharmaceuticals GmbH (www.cevec.com) offers an innovative human cell expression system - CAP(R) Technology. The patented human cell lines are used for the production of gene therapy vectors, therapeutic proteins and novel innovative vaccines. A number of licensing transactions, both for R&D and clinical purposes, have already been concluded. CEVEC has recently formed a CMO joint venture partnership with GenIBet, Portugal for cGMP production services based on CAP(R) Technology.
Contact:
CEVEC Pharmaceuticals GmbH
Frank Ubags
Chief Executive Officer
T.:+49 221 46020800
E.: ubags@cevec.com
MC Services AG
Anne Hennecke
Public Relations
T.: +49 211 52925222
E.: anne.hennecke@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.